Related Experiment Video

Updated: Nov 21, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies

Yonina R Murciano-Goroff1, Alexander Drilon2, Zsofia K Stadler2

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cancer Cell
|January 12, 2021
PubMed

Insights

The National Cancer Institute (NCI) - Molecular Analysis for Therapy Choice (MATCH) trial shows it is feasible to identify genetic mutations in tumors for targeted cancer therapy. This approach strengthens academic and community partnerships to improve patient access to clinical trials.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • Precision medicine aims to tailor cancer treatments based on individual tumor genetic profiles.
  • Identifying actionable genetic alterations in diverse tumor types is crucial for effective targeted therapy.

Purpose of the Study:

  • To assess the feasibility of a national master protocol trial for molecularly guided cancer therapy.
  • To determine the ability to identify actionable genetic alterations in a broad range of cancers.
  • To evaluate the role of academic and community partnerships in enhancing clinical trial access.

Main Methods:

  • The National Cancer Institute (NCI) - Molecular Analysis for Therapy Choice (MATCH) trial employed broad tumor sequencing.
  • Patients were assigned to treatment arms based on identified genetic alterations.
  • The study involved a collaboration between academic institutions and community cancer centers.

Main Results:

  • The trial successfully demonstrated the feasibility of its master protocol design.
  • Actionable genetic alterations, both common and rare, were identified across diverse tumor types.
  • The study highlighted the effectiveness of academic/community partnerships in patient recruitment and trial execution.

Conclusions:

  • Molecular profiling and targeted therapy assignment are feasible in a large-scale national trial.
  • The NCI-MATCH trial provides a framework for precision oncology initiatives.
  • Collaborative efforts between academic and community settings are vital for advancing cancer clinical trials and improving patient outcomes.

More Related Videos

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.6K
Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
871
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K